Septerna (NASDAQ:SEPN) Stock Price Up 4.8% – Here’s What Happened

Septerna, Inc. (NASDAQ:SEPN) was up 4.8% during trading on Wednesday . The stock traded as high as $39.19 and last traded at $39.1640. 82,861 shares changed hands during trading, a decline of 77% from the average session volume of 358,067 shares. The stock had previously closed at $37.37.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on SEPN shares. Raymond James Financial restated a “strong-buy” rating and set a $49.00 price target on shares of Septerna in a report on Tuesday, August 11th. Stifel Nicolaus set a $49.00 price target on shares of Septerna in a research note on Tuesday, August 11th. Wells Fargo & Company raised their target price on Septerna from $48.00 to $50.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a report on Friday, July 17th. Finally, JonesTrading boosted their price objective on Septerna from $43.00 to $62.00 and gave the company a “buy” rating in a report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $52.44.

Septerna Price Performance

The company has a market cap of $1.76 billion, a P/E ratio of -69.91 and a beta of 2.30. The stock has a fifty day moving average price of $37.70 and a two-hundred day moving average price of $31.47.

Septerna (NASDAQ:SEPN) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.14. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.57%. The firm had revenue of $26.75 million for the quarter, compared to the consensus estimate of $19.22 million. Equities analysts predict that Septerna, Inc. will post -1.41 earnings per share for the current fiscal year.

Insider Buying and Selling at Septerna

In other Septerna news, insider Samira Shaikhly sold 2,178 shares of Septerna stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $35.18, for a total value of $76,622.04. Following the sale, the insider owned 793 shares of the company’s stock, valued at approximately $27,897.74. The trade was a 73.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Daniel D. Long sold 15,000 shares of the business’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $35.51, for a total transaction of $532,650.00. Following the completion of the transaction, the senior vice president owned 96,412 shares in the company, valued at approximately $3,423,590.12. The trade was a 13.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 52,178 shares of company stock worth $2,064,804 in the last quarter. 5.80% of the stock is currently owned by company insiders.

Institutional Trading of Septerna

Hedge funds have recently made changes to their positions in the company. Group One Trading LLC raised its stake in Septerna by 111.8% in the 4th quarter. Group One Trading LLC now owns 944 shares of the company’s stock valued at $26,000 after acquiring an additional 8,955 shares during the period. Global Retirement Partners LLC purchased a new stake in shares of Septerna during the 4th quarter valued at approximately $35,000. Russell Investments Group Ltd. purchased a new position in Septerna in the 3rd quarter valued at approximately $36,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Septerna in the fourth quarter worth about $53,000. Finally, BNP Paribas Financial Markets boosted its position in shares of Septerna by 88.0% in the third quarter. BNP Paribas Financial Markets now owns 4,155 shares of the company’s stock valued at $78,000 after acquiring an additional 1,945 shares during the period.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.